Chong Kun Dang Pharmaceutical Corp.
š°š·South Korea
- Country
- š°š·South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)
Phase 1
Completed
- Conditions
- Central Nervous System Diseases
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 20
- Registration Number
- NCT03569579
- Locations
- š°š·
Chonbuk National University Hospital, Jeonju, Korea, Republic of
A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects
Phase 1
Completed
- Conditions
- GERD
- Interventions
- Drug: D026Drug: CKD-381
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 41
- Registration Number
- NCT03558425
- Locations
- š°š·
Seoul Nat'l University Hospital, Seoul, Korea, Republic of
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- GERD
- Interventions
- Drug: CKD-381(formulation I)Drug: CKD-381(formulation II)Drug: D026(Nexium 40mg)
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 18
- Registration Number
- NCT03444402
- Locations
- š°š·
Seoul University Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet
Phase 2
Completed
- Conditions
- Gastritis
- Interventions
- Drug: CKD-495 75mgDrug: CKD-495 150mgDrug: Artemisiae argyi folium 95% ethanol ext.(20ā1) 60mgDrug: Rebamipide 100mgDrug: Placebo of the CKD-495 150mgDrug: Placebo of the CKD-495 75mgDrug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20ā1) 60mgDrug: Placebo of the Rebamipide 100mg
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 250
- Registration Number
- NCT03437785
- Locations
- š°š·
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, Korea, Republic of
š°š·Hallym University Chuncheon Seonsim Hospital, Chuncheon, Korea, Republic of
š°š·Yeungnam University Medical Center, Daegu, Korea, Republic of
CKD-11101 Phase 3 SC Study
Phase 3
Completed
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Biological: CKD-11101(Darbepoetin alfa)Biological: NESP(Darbepoetin alfa)
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 248
- Registration Number
- NCT03431623
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
Phase 3
Completed
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Biological: NESPBiological: CKD-11101
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 403
- Registration Number
- NCT03428594
A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337
Phase 1
Completed
- Conditions
- Dyslipidemias
- Interventions
- Dietary Supplement: High fat dietDrug: CKD-337
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 16
- Registration Number
- NCT03382756
- Locations
- š°š·
Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
Phase 1
Completed
- Conditions
- Dyslipidemias
- Interventions
- Drug: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)Drug: Test drug(CKD-337)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT03346187
- Locations
- š°š·
Dong-A University Hospital, Busan, Seo-gu, Korea, Republic of
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
Phase 3
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 455
- Registration Number
- NCT03246880
- Locations
- š°š·
Asan Medical Center, Seoul, Korea, Republic of
CKD-841 Pharmacokinetic/Pharmacodynamic Study
Phase 1
Completed
- Conditions
- Postmenopausal Disorder
- Interventions
- Drug: Leuplinā”InjDrug: CKD-841
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 13
- Registration Number
- NCT03233932
- Locations
- š°š·
Severance Hospital, Seoul, Yonsei-ro, Seodaemun-gu 50-1, Korea, Republic of
Ā© Copyright 2025. All Rights Reserved by MedPath